血浆可溶性ST2与急性低氧性呼吸衰竭患者脱机相关
该研究纳入200例急性低氧性呼吸衰竭患者,每日检测血浆sST2和IL-6至插管后9天。基线sST2较高者第29天无辅助呼吸比例更低,sST2随时间升高与脱机概率降低独立相关,脱机日sST2升高者脱机失败风险增加,而IL-6与结局无关。提示sST2可能优于传统生理指标指导脱机决策。
要点
- 基线sST2较高与第29天无辅助呼吸率降低相关。
- sST2随时间升高独立预测脱机概率下降。
- 脱机日sST2升高者脱机失败风险增加,IL-6无此关联。
核心结论
- 血浆sST2浓度与急性低氧性呼吸衰竭患者脱机结局独立相关,可能比传统生理评估更准确反映肺损伤。
研究设计与样本
- 前瞻性队列研究,纳入200例急性低氧性呼吸衰竭患者,插管后最多9天每日检测血浆sST2和IL-6及生理变量。
主要发现
- 基线sST2在死亡或机械通气患者中为491.7 ng/ml(IQR 294.5-670.1),高于无辅助呼吸者的314.4 ng/ml(IQR 127.5-550.1),P=0.0003。
- sST2每增加一个对数单位,脱机概率的风险比为0.80(95%CI 0.75-0.83),P=0.03。
- 脱机日sST2较高者失败率为320.9 ng/ml(IQR 181.1-495.6),成功者为161.6 ng/ml(IQR 95.8-292.5),P=0.002。
- 调整标准生理参数后,脱机日sST2升高降低成功脱机 odds(OR 0.325,95%CI 0.119-0.885,P=0.03)。
- IL-6浓度与结局无关联。
关键数值与推荐
- 基线sST2较高与第29天死亡或机械通气相关(P=0.0003)。
- sST2随时间升高与脱机概率降低相关(HR 0.80 per log-unit,95%CI 0.75-0.83,P=0.03)。
- 脱机日sST2升高与脱机失败相关(P=0.002),调整后OR 0.325(95%CI 0.119-0.885,P=0.03)。
临床怎么用
- 可考虑监测血浆sST2辅助评估急性低氧性呼吸衰竭患者的脱机时机,尤其当传统生理指标不确定时。
局限性
- 单中心研究,样本量200例,需外部验证。
- 仅检测插管后9天内生物标志物,长期动态未评估。
- IL-6未显示关联,但未报告其他炎症标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Standard physiologic assessments of extubation readiness in patients with acute hypoxemic respiratory failure (AHRF) may not reflect lung injury resolution and could adversely affect clinical decision-making and patient outcomes. Objectives: We hypothesized that elevations in inflammatory plasma biomarkers sST2 (soluble suppression of tumorigenicity-2) and IL-6 indicate ongoing lung injury in AHRF and better inform patient outcomes compared with standard clinical assessments. Methods: We measured daily plasma biomarkers and physiologic variables in 200 patients with AHRF for up to 9 days after intubation. We tested the associations of baseline values with the primary outcome of unassisted breathing at Day 29. We analyzed the ability of serial biomarker measurements to inform successful ventilator liberation. Measurements and Main Results: Baseline sST2 concentrations were higher in patients dead or mechanically ventilated versus breathing unassisted at Day 29 (491.7 ng/ml [interquartile range (IQR), 294.5-670.1 ng/ml] vs. 314.4 ng/ml [IQR, 127.5-550.1 ng/ml]; P = 0.0003). Higher sST2 concentrations over time were associated with a decreased probability of ventilator liberation (hazard ratio, 0.80 per log-unit increase; 95% confidence interval [CI], 0.75-0.83; P = 0.03). Patients with higher sST2 concentrations on the day of liberation were more likely to fail liberation compared with patients who remained successfully liberated (320.9 ng/ml [IQR, 181.1- 495.6 ng/ml] vs. 161.6 ng/ml [IQR, 95.8-292.5 ng/ml]; P = 0.002). Elevated sST2 concentrations on the day of liberation decreased the odds of successful liberation when adjusted for standard physiologic parameters (odds ratio, 0.325; 95% CI, 0.119-0.885; P = 0.03). IL-6 concentrations did not associate with outcomes. Conclusions: Using sST2 concentrations to guide ventilator management may more accurately reflect underlying lung injury and outperform traditional measures of readiness for ventilator liberation.
引用
- Alladina J, Levy SD, Cho JL, et al. Plasma Soluble Suppression of Tumorigenicity-2 Associates with Ventilator Liberation in Acute Hypoxemic Respiratory Failure. Am J Respir Crit Care Med. 2021. PMID: 33400890. doi:10.1164/rccm.202005-1951OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。